Jonathan P Piccini
Jonathan P Piccini is an expert in Cardiology at Duke Medical Center (United States). As of October 2026, ScienceLeadR ranks Jonathan P Piccini in the top 1% of experts worldwide for Atrial Fibrillation, Atrial Flutter and Arrhythmias, Cardiac. Jonathan P Piccini has authored 947 publications, the most recent in 2026, and is an investigator in 38 clinical trials, 1 of them ongoing. SLR score: 4,176 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Public Health - Pharmacy - Neurology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Jonathan P. Piccini, MD, MHS, FACC, FAHA, FHRS is a clinical cardiac electrophysiologist and Professor of Medicine at Duke University and the Duke Clinical Research Institute. He is the Director of the Cardiac Electrophysiology section at the Duke Heart Center. His focus is on the care of patients with atrial fibrillation and complex arrhythmias, with particular emphasis on catheter ablation, pacing, and lead extraction. His research interests include the development and evaluation of innovative cardiovascular interventions for the treatment of heart rhythm disorders. He has served on the Board of Trustees of the Heart Rhythm Society, is an Associate Editor at JACC: Clinical Electrophysiology, and is an elected member of the American Society for Clinical Investigation. Dr. Piccini has more than 600 publications in the field of heart rhythm medicine.
Organizations
Career arc: 2004 - 2026
Number : 947
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Use of Anticoagulation Among Patients With Atrial Fibrillation or Atrial Flutter in the United States. PMID 42852510 — atrial flutter, hemorrhage, ischemic stroke, stroke, prescriptions, atrial fibrillation, odds ratio, diagnosis, warfarin, direct-acting oral anticoagulants | Circ Popul Health Outcomes | 2026 | 0 |
| ECG characteristics and stellate ganglion blockade for electrical storm. PMID 42774723 — stellate ganglion, ganglion cysts | Heart Rhythm O2 | 2026 | 0 |
| Frequency and Extent of Leadless Pacemaker Encapsulation. PMID 42720635 — cardiovascular diseases, tissues | JACC Clin Electrophysiol | 2026 | 0 |
| Redefining atrial fibrillation treatment success: patient-defined goals for arrhythmia burden and health-related quality of life. PMID 42683919 — quality of life, arrhythmias, cardiac, cardiovascular diseases, atrial fibrillation, sex, therapeutics | Crit Pathw Cardiol | 2026 | 0 |
| Safety and Effectiveness of a Novel Dual-Energy Radiofrequency/Pulsed Field Ablation Catheter: 12 Month Results of the FlexPulse Study. PMID 42667242 — safety, pharmaceutical preparations, atrial fibrillation, catheter ablation, catheters, pulsed field ablation | Europace | 2026 | 0 |
Clinical Studies 38
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Pulsed Field Ablation (PFA) vs Anti Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation NCT06096337 — pulmonary veins, heart diseases, pharmaceutical preparations, propafenone, heart, cardiovascular diseases, sotalol, atrial fibrillation, anti-arrhythmia agents, drug delivery systems, therapeutics, flecainide, veins, dronedarone, pulsed field ablation | N/A | Active not recruiting | 2023 |
LeadR Networks
Main global connection map